Foldikines™: Reprogramming the Immune System Like Software Code
Cytokines are the immune system’s messengers, sending signals to direct immune responses. But in many diseases, these signals go wrong, much like in a faulty software program that starts producing errors.
Orikine Bio’s Foldikine™ platform works by engineering cytokines that act like "patches" in a malfunctioning computer program, fixing the faulty signals and restoring the immune system to its proper function.
News and events
Orikine Presents Preclinical Data Demonstrating Sustained Myeloid Reprogramming and Disease Control with ORK1 in Inflammatory Bowel Disease at UEG Week 2026
• A single dose of ORK1 generated durable disease control in two independent inflammatory bowel disease mouse models • ORK1 induced sustained myeloid reprogramming, regulating chronic inflammation • This data supports further development of ORK1 as it progresses towards IND-enabling studies
20 October, 2026Orikine appoints new CEO and Leadership Team to advance ORK1 in Autoimmune Disease
• Sabrina Kuttruff-Coqui appointed Chief Executive Officer, Joachim Koch appointed Chief Scientific and Development Officer and Andreas Muehler joining as Chief Medical Officer • Expanded leadership team brings decades of expertise in translating scientific innovation into clinical-stage programs and building biotechnology companies
08 September, 2026Orikine Bio appoints Larry Edwards as Chairman of the Board
Barcelona, Spain, 20 January 2026. Orikine Bio, a biotechnology company based at the Barcelona Science Park (PCB-UB), today announced the appointment of Larry Edwards as Chairman of its Board of Directors, effective 1 January 2026. His incorporation strengthens the company’s governance and supports its strategic vision as it advances toward key clinical and corporate milestones.
20 January, 2026
Join us
At Orikine Bio, we are pioneering the future of cytokine-based therapies, pushing the boundaries of science and biology to develop groundbreaking solutions for autoimmune and inflammatory diseases. Our success is driven by the passion, creativity, and scientific rigor of our team. If you are excited about joining a company at the forefront of biotechnology, where innovation meets impact, Orikine is the place for you.
Investors
This company is capitalized by INNVIERTE, AN INVESTMENT PROGRAM OF CDTI, E.P.E.
Grants
Project CPP2023-010468 financed by MICIU/AEI/10.13039/501100011033; Project CPP2024-011392 financed by MICIU/AEI/10.13039/501100011033
PTQ2022-012499 awarded by MCIU/AEI / 10.13039/501100011033; PTQ2023-012951 awarded by MICIU/AEI / 10.13039/501100011033
Project SNEO-20241312 financed by Centro para el Desarrollo Tecnológico y la Innovación E.P.E. (CDTI) in the context of Plan Estatal de Investigación Científica y Técnica y de Innovación